In a report released on April 15, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Edwards Lifesciences (EW – Research Report), ...

Edwards Lifescienes also reported a big increase in pay for the structural heart device developer and manufacturer's median ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received ...

Citi analyst Joanne Wuensch maintained a Buy rating on Edwards Lifesciences (EW – Research Report) today. The company’s shares closed yesterday ...

Edwards SAPIEN M3 mitral valve replacement system receives CE Mark for transcatheter treatment: Irvine, California Wednesday, ...

Edwards Lifesciences announced today that it received CE mark approval for its Sapien M3 mitral valve replacement system.

Barclays, in a report, says that Abbott (NYSE:ABT) and Baxter (NYSE:BAX) will be among least affected, while Johnson & ...

Edwards’ device, dubbed Sapien M3, is the first approved system to use a transfemoral approach to treating mitral ...

Edwards Lifesciences Corp. closed 28.34% below its 52-week high of $95.25, which the company achieved on July 11th.

The Irvine-based medical device maker today announced that it received CE mark approval for its Sapien M3 mitral replacement ...

There’s room on the market for new TAVI valves as long as they can compete with the best in practice, a researcher says.